Bristol-Myers: Looking To Maintain Lead In Immunotherapy – Seeking Alpha
Seeking Alpha |
Bristol-Myers: Looking To Maintain Lead In Immunotherapy
Seeking Alpha The phase 2 study with accelerated approval shows the true power of Opdivo as an immunotherapy product. Competition from KEYTRUDA will be fierce in the colorectal cancer space. On Tuesday, Bristol-Myers (BMY) won approval for microsatellite … |
